- Home
- IPHA vs TLSA Comparison
IPHA vs TLSA Comparison
Compare IPHA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- TLSA
- Stock Information
- Founded
- IPHA 1999
- TLSA 2013
- Country
- IPHA France
- TLSA United Kingdom
- Employees
- IPHA N/A
- TLSA N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- TLSA Health Care
- Exchange
- IPHA Nasdaq
- TLSA Nasdaq
- Market Cap
- IPHA 160.1M
- TLSA 187.0M
- IPO Year
- IPHA 2019
- TLSA 2000
- Fundamental
- Price
- IPHA $2.11
- TLSA $2.39
- Analyst Decision
- IPHA Strong Buy
- TLSA
- Analyst Count
- IPHA 1
- TLSA 0
- Target Price
- IPHA $11.00
- TLSA N/A
- AVG Volume (30 Days)
- IPHA 13.4K
- TLSA 385.1K
- Earning Date
- IPHA 09-11-2025
- TLSA 08-12-2025
- Dividend Yield
- IPHA N/A
- TLSA N/A
- EPS Growth
- IPHA N/A
- TLSA N/A
- EPS
- IPHA N/A
- TLSA N/A
- Revenue
- IPHA $20,831,349.00
- TLSA N/A
- Revenue This Year
- IPHA $278.51
- TLSA N/A
- Revenue Next Year
- IPHA $70.16
- TLSA N/A
- P/E Ratio
- IPHA N/A
- TLSA N/A
- Revenue Growth
- IPHA N/A
- TLSA N/A
- 52 Week Low
- IPHA $1.29
- TLSA $0.63
- 52 Week High
- IPHA $3.51
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- IPHA 60.15
- TLSA 76.33
- Support Level
- IPHA $1.71
- TLSA $2.04
- Resistance Level
- IPHA $2.63
- TLSA $2.60
- Average True Range (ATR)
- IPHA 0.14
- TLSA 0.19
- MACD
- IPHA 0.03
- TLSA 0.08
- Stochastic Oscillator
- IPHA 41.83
- TLSA 84.48
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.